Cochrane · systematic review · CD010252
Antibody induction versus corticosteroid induction for liver transplant recipients
Penninga, L, Wettergren, A, Wilson, CH, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
8
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 8 · 100%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
T‐cell antibody induction compared with corticosteroid induction for liver transplant recipients
Population: liver transplant recipients.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Mortality at latest T‐cell antibody induction vs corticosteroid induction | RR 1.01 [0.72, 1.43] | 10 studies · 1589 participants | Low Downgraded: risk of bias |
Graft loss Graft loss (including death with a functioning graft) at latest T‐cell antibody induction vs corticosteroid induction | RR 1.12 [0.82, 1.53] | 10 studies · 1589 participants | Low Downgraded: risk of bias |
Acute rejection Number of participants who experienced at least 1 episode of rejection T‐cell antibody induction vs corticosteroid induction | RR 0.84 [0.7, 1] | 10 studies · 1589 participants | Low Downgraded: risk of bias |
Infection Number of participants who experienced at least 1 episode of infection T‐cell antibody induction vs corticosteroid induction | RR 0.88 [0.71, 1.08] | 5 studies · 1164 participants | Low Downgraded: risk of bias |
Cytomegalovirus infection Number of participants who experienced at least 1 episode of CMV infection T‐cell antibody induction vs corticosteroid induction | RR 0.5 [0.33, 0.75] | 5 studies · 1164 participants | Low Downgraded: risk of bias |
Hepatitis C recurrence Number of participants diagnosed with hepatitis C virus recurrence T‐cell antibody induction vs corticosteroid induction | RR 0.89 [0.79, 1] | 6 studies · 522 participants | Low Downgraded: risk of bias |
Malignancy Number of participants diagnosed with a malignancy T‐cell antibody induction vs corticosteroid induction | RR 0.59 [0.13, 2.73] | 6 studies · 1210 participants | Low Downgraded: risk of bias |
Diabetes mellitus Number of participants with new‐onset diabetes mellitus T‐cell antibody induction vs corticosteroid induction | RR 0.45 [0.34, 0.6] | 10 studies · 1579 participants | Low Downgraded: risk of bias |